Linee guida Linee guida per la diagnosi e - Cardiologia interventistica

G Ital Cardiol Vol 8 Ottobre 2007
tiplatelet therapy following percutaneous coronary intervention:
a randomized controlled trial. JAMA 2002; 288:
2411-20.
220. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ,
Yusuf S. Benefits and risks of the combination of clopidogrel
and aspirin in patients undergoing surgical revascularization
for non-ST-elevation acute coronary syndrome: the
Clopidogrel in Unstable angina to prevent Recurrent ischemic
Events (CURE) Trial. Circulation 2004; 110:
1202-8.
221. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli
J, Dotzer F, Ten Berg JM, Neumann FJ, Bollwein H,
Dirschinger J, Schomig A. Influence of treatment duration
with a 600-mg dose of clopidogrel before percutaneous
coronary revascularization. J Am Coll Cardiol 2004; 44:
2133-6.
222. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C,
Lellouche N, Steg PG, Slama M, Milleron O, Collet JP,
Henry P, Beygui F, Drouet L. A randomized comparison of
high clopidogrel loading doses in patients with non-ST-segment
elevation acute coronary syndromes: the ALBION
(Assessment of the Best Loading Dose of Clopidogrel to
Blunt Platelet Activation, Inflammation and Ongoing
Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-8.
223. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di
Sciascio G. Randomized trial of high loading dose of clopidogrel
for reduction of periprocedural myocardial infarction
in patients undergoing coronary intervention: results
from the ARMYDA-2 (Antiplatelet therapy for Reduction
of MYocardial Damage during Angioplasty) study. Circulation
2005; 111: 2099-106.
224. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig
E, Kastrati A, Schomig A. Absorption, metabolization, and
antiplatelet effects of 300-, 600-, and 900-mg loading doses
of clopidogrel: results of the ISAR-CHOICE (Intracoronary
Stenting and Antithrombotic Regimen: Choose Between 3
High Oral Doses for Immediate Clopidogrel Effect) Trial.
Circulation 2005; 112: 2946-50.
225. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina
CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann
FJ. Impact of the degree of peri-interventional platelet inhibition
after loading with clopidogrel on early clinical outcome
of elective coronary stent placement. J Am Coll Cardiol
2006; 48: 1742-50.
226. Szuk T, Gyongyosi M, Homorodi N, Kristof E, Kiraly C,
Edes IF, Facsko A, Pavo N, Sodeck G, Strehblow C, Farhan
S, Maurer G, Glogar D, Domanovits H, Huber K, Edes I.
Effect of timing of clopidogrel administration on 30-day
clinical outcomes: 300-mg loading dose immediately after
coronary stenting versus pretreatment 6 to 24 h before stenting
in a large unselected patient cohort. Am Heart J 2007;
153: 289-95.
227. SYMPHONY Investigators. Comparison of sibrafiban with
aspirin for prevention of cardiovascular events after acute
coronary syndromes: a randomised trial. The SYMPHONY
Investigators. Sibrafiban versus Aspirin to Yield Maximum
Protection from Ischemic Heart Events Post-acute Coronary
Syndromes. Lancet 2000; 355: 337-45.
228. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf
RM, Graffagnino C, Davis S, Diener HC, Ferguson J,
Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P,
Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT.
Randomized, double-blind, placebo-controlled, international
trial of the oral IIb/IIIa antagonist lotrafiban in coronary
and cerebrovascular disease. Circulation 2003; 108:
399-406.
229. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux
P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin
LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML.
664
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary
syndromes: a meta-analysis of all major randomised clinical
trials. Lancet 2002; 359: 189-98.
230. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno
DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman
NS, Theroux P, White HD, Topol EJ. Platelet glycoprotein
IIb/IIIa inhibition in acute coronary syndromes. Gradient of
benefit related to the revascularization strategy. Eur Heart J
2002; 23: 1441-8.
231. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol
EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition
in non-ST-elevation acute coronary syndromes:
early benefit during medical treatment only, with additional
protection during percutaneous coronary intervention. Circulation
1999; 100: 2045-8.
232. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD,
Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V,
Topol EJ. Clinical outcomes of therapeutic agents that block
the platelet glycoprotein IIb/IIIa integrin in ischemic heart
disease. Circulation 1998; 98: 2829-35.
233. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA,
Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White
HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein
IIb/IIIa inhibitors reduce mortality in diabetic patients
with non-ST-segment-elevation acute coronary syndromes.
Circulation 2001; 104: 2767-71.
234. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker
abciximab on outcome in patients with acute coronary
syndromes without early coronary revascularisation: the
GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-
24.
235. PURSUIT Investigators. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary
syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein
IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy. N Engl J Med 1998; 339:
436-43.
236. PRISM Investigators. A comparison of aspirin plus
tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management
(PRISM) Study Investigators. N Engl J Med 1998;
338: 1498-505.
237. PRISM PLUS Investigators. Inhibition of the platelet glycoprotein
IIb/IIIa receptor with tirofiban in unstable angina
and non-Q-wave myocardial infarction. Platelet Receptor
Inhibition in Ischemic Syndrome Management in Patients
Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Study Investigators. N Engl J Med 1998; 338: 1488-97.
238. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng
JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of
survival with platelet glycoprotein IIb/IIIa antagonists for
percutaneous coronary interventions. Am J Cardiol 2003;
92: 651-5.
239. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous
coronary revascularization. The EPILOG Investigators.
N Engl J Med 1997; 336: 1689-96.
240. EPISTENT Investigators. Randomised placebo-controlled
and balloon-angioplasty-controlled trial to assess safety of
coronary stenting with use of platelet glycoprotein-IIb/IIIa
blockade. The EPISTENT Investigators. Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352:
87-92.
241. Lincoff AM, Califf RM, Anderson KM, Weisman HF,
Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Evidence
for prevention of death and myocardial infarction
with platelet membrane glycoprotein IIb/IIIa receptor
blockade by abciximab (c7E3 Fab) among patients with unstable
angina undergoing percutaneous coronary revascu-